-DOCSTART- -X- O
Background. -X- _ O
Parainfluenza -X- _ O
virus -X- _ O
( -X- _ O
PIV -X- _ O
) -X- _ O
commonly -X- _ O
infects -X- _ O
patients -X- _ B-Patient
following -X- _ I-Patient
hematopoietic -X- _ I-Patient
cell -X- _ I-Patient
transplantation -X- _ I-Patient
( -X- _ I-Patient
HCT -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
frequently -X- _ O
causing -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
disease -X- _ O
( -X- _ O
LRTD -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
definition -X- _ O
of -X- _ O
LRTD -X- _ O
significantly -X- _ O
differs -X- _ O
among -X- _ O
studies -X- _ O
evaluating -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
PIV -X- _ B-Patient
after -X- _ I-Patient
HCT. -X- _ I-Patient
Methods. -X- _ O
We -X- _ O
retrospectively -X- _ O
evaluated -X- _ O
544 -X- _ B-Patient
HCT -X- _ I-Patient
recipients -X- _ I-Patient
with -X- _ O
laboratory-confirmed -X- _ O
PIV -X- _ O
and -X- _ O
classified -X- _ O
LRTD -X- _ O
into -X- _ O
3 -X- _ O
groups -X- _ O
: -X- _ O
possible -X- _ O
( -X- _ O
PIV -X- _ O
detection -X- _ O
in -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
with -X- _ O
new -X- _ O
pulmonary -X- _ O
infiltrates -X- _ O
with -X- _ O
/ -X- _ O
without -X- _ O
LRTD -X- _ O
symptoms -X- _ O
) -X- _ O
, -X- _ O
probable -X- _ O
( -X- _ O
PIV -X- _ O
detection -X- _ O
in -X- _ O
lung -X- _ O
with -X- _ O
LRTD -X- _ O
symptoms -X- _ O
without -X- _ O
new -X- _ O
pulmonary -X- _ O
infiltrates -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
proven -X- _ O
( -X- _ O
PIV -X- _ O
detection -X- _ O
in -X- _ O
lung -X- _ O
with -X- _ O
new -X- _ O
pulmonary -X- _ O
infiltrates -X- _ O
with -X- _ O
/ -X- _ O
without -X- _ O
LRTD -X- _ O
symptoms -X- _ O
) -X- _ O
. -X- _ O
Results. -X- _ O
Probabilities -X- _ B-Outcome
of -X- _ I-Outcome
90-day -X- _ I-Outcome
survival -X- _ I-Outcome
after -X- _ I-Outcome
LRTD -X- _ I-Outcome
were -X- _ I-Outcome
87 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
58 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
45 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
possible -X- _ I-Outcome
, -X- _ I-Outcome
probable -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
proven -X- _ I-Outcome
cases -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Patients -X- _ I-Outcome
with -X- _ I-Outcome
probable -X- _ I-Outcome
and -X- _ I-Outcome
proven -X- _ I-Outcome
LRTD -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
worse -X- _ I-Outcome
survival -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
with -X- _ I-Outcome
upper -X- _ I-Outcome
respiratory -X- _ I-Outcome
tract -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
probable -X- _ I-Outcome
: -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
[ -X- _ I-Outcome
HR -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
5.87 -X- _ I-Outcome
[ -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.001 -X- _ I-Outcome
] -X- _ I-Outcome
; -X- _ I-Outcome
proven -X- _ I-Outcome
: -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
9.23 -X- _ I-Outcome
[ -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.001 -X- _ I-Outcome
] -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
possible -X- _ I-Outcome
LRTD -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
( -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
1.49 -X- _ I-Outcome
[ -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.27 -X- _ I-Outcome
] -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Among -X- _ I-Outcome
proven -X- _ I-Outcome
/ -X- _ I-Outcome
probable -X- _ I-Outcome
cases -X- _ I-Outcome
, -X- _ I-Outcome
oxygen -X- _ I-Outcome
requirement -X- _ I-Outcome
at -X- _ I-Outcome
diagnosis -X- _ I-Outcome
, -X- _ I-Outcome
low -X- _ I-Outcome
monocyte -X- _ I-Outcome
counts -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
high-dose -X- _ I-Outcome
steroid -X- _ I-Outcome
use -X- _ I-Outcome
( -X- _ I-Outcome
> -X- _ I-Outcome
2 -X- _ I-Outcome
mg -X- _ I-Outcome
/ -X- _ I-Outcome
kg -X- _ I-Outcome
/ -X- _ I-Outcome
day -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
high -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
multivariable -X- _ I-Outcome
analysis. -X- _ I-Outcome
Conclusions. -X- _ O
PIV -X- _ B-Outcome
LRTD -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
detection -X- _ I-Outcome
in -X- _ I-Outcome
lungs -X- _ I-Outcome
( -X- _ I-Outcome
proven -X- _ I-Outcome
/ -X- _ I-Outcome
probable -X- _ I-Outcome
LRTD -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
worse -X- _ I-Outcome
outcomes -X- _ I-Outcome
than -X- _ I-Outcome
was -X- _ I-Outcome
PIV -X- _ I-Outcome
LRTD -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
detection -X- _ I-Outcome
in -X- _ I-Outcome
upper -X- _ I-Outcome
respiratory -X- _ I-Outcome
samples -X- _ I-Outcome
alone -X- _ I-Outcome
( -X- _ I-Outcome
possible -X- _ I-Outcome
LRTD -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
This -X- _ O
new -X- _ O
classification -X- _ O
should -X- _ O
impact -X- _ O
clinical -X- _ O
trial -X- _ O
design -X- _ O
and -X- _ O
permit -X- _ O
comparability -X- _ O
of -X- _ O
results -X- _ O
among -X- _ O
centers -X- _ O
. -X- _ O

